The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback